BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 110,600 shares, an increase of 7.3% from the August 15th total of 103,100 shares. Approximately 1.4% of the company’s stock are sold short. Based on an average daily volume of 136,800 shares, the short-interest ratio is currently 0.8 days.
Institutional Trading of BioNexus Gene Lab
An institutional investor recently raised its position in BioNexus Gene Lab stock. Virtu Financial LLC boosted its position in BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 79.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,037 shares of the company’s stock after purchasing an additional 20,888 shares during the period. Virtu Financial LLC owned about 0.27% of BioNexus Gene Lab worth $33,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 18.85% of the company’s stock.
BioNexus Gene Lab Stock Up 1.4 %
Shares of BGLC stock opened at $0.45 on Tuesday. BioNexus Gene Lab has a 52-week low of $0.31 and a 52-week high of $3.39. The company has a 50-day simple moving average of $0.45 and a two-hundred day simple moving average of $0.55.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
See Also
- Five stocks we like better than BioNexus Gene Lab
- How to Invest in the FAANG Stocks
- Lock In Gains: Apple Stock Could Rally 30% Before the Holidays
- Energy and Oil Stocks Explained
- How to Apply Trading Volume Analysis to Stock Trading
- What Is WallStreetBets and What Stocks Are They Targeting?
- Market Got It Wrong—Why Progress Software Deserves a Second Look
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.